Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: C Wright who wrote (5093)	11/18/1997 12:25:00 AM
From: Galirayo	Read Replies (1) \| Respond to of 9262

Hi, Carol. I won't even consider FIBR. Not at all. It has a closet full of stuff. Ray

To: C Wright who wrote (5093)	11/18/1997 12:36:00 AM
From: John Metcalf	Read Replies (1) \| Respond to of 9262

Hi, Carol. I heard from Rick today, landed in Bay Area, having survived Hurricane Rick (not making this up-:) When he collects his wits (and computer) I hope he'll add to this. ARIA is a high quality biotech, but very early in its development. The main event this year has been the funding of a genomics center by Hoescht-Marion-Roussel which is just beginning now. The scientists are the world's best (Gerald Crabtree of Stanford and Stuart Schreiber of Harvard), the patent position is novel and promising, and the venture has ample capital. There are no near-term prospects, but the fundamental science shows potential for dominance of the field of genomics. Two other quality biotechs made tonight's lists. Celgene has made a number of advancements on the science front, improved the balance sheet, and is on the verge of Thalidomide approval for use with leprosy. KDUS (Cadus) is a chemistry company, which may rise to the ranks of Aurora (ABSC) or ArQule (ARQL).